Idogen extends the project portfolio to projects in autoimmune diseases
Idogen AB (”Idogen”) announces today that the company has decided to expand its project portfolio with a third therapeutic area; autoimmune diseases. Idogen´s research department is currently evaluating the potential of the company's technology in a group of autoimmune diseases where there is a major medical need, and where a treatment has the potential to be granted orphan drug status.Idogen´s technology is designed for the development of tolerogenic cell therapy in a variety of areas, especially treatment of anti-drug antibodies, autoimmune diseases and organ rejection after